Detailed price information for Sab Biotherapeutics Inc (SABS-Q) from The Globe and Mail including charting and trades.

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...

Warde Manuel will step down as the University of Michigan’s athletic director at the end of the year. (July 20, 2026) ...

Under the terms of MacroGenics’ agreement with Sanofi, the recent FDA approval triggered a $24.5 million regulatory milestone payable to MacroGenics. The Company remains eligible to receive up to $305 ...

A.J. Evans and Phil Pinarski discuss some of the bright spots in Summer League and they try to figure out where LeBron James ...

Brazil patent complements U.S. patent portfolio for NCEL-101, strengthening global position in the type 1 diabetes market. ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ( ...

Spero Therapeutics gets a Buy on the immunology pivot, FDA-approved Utebzi, and $105M royalty deal funding SP001. Learn more ...

The NHS begins offering teplizumab, the first drug shown to delay type 1 diabetes and postpone insulin by nearly three years.

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials ...

Life has a way of testing our patience, but the strongest responses are often rooted in compassion. Psychology shows that ...